The news is in, and it is bad. It is as bad as many of us feared. The National Institute of Health (NIH) has announced that their across-the-board budget sequester cuts are going to equal 1.71 billion dollars. The NIH is responsible for the majority of cancer research performed in the United States. For the [...]
The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. Their criteria for inclusion included randomized, controlled trials of intermittent hormone therapy (IADT) as compared to continuous hormone therapy (CADT) [...]
Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]
Currently as our advanced prostate cancer progresses and we develop bone and soft tissue tumors our pain increases significantly. Current treatment options for the palliation of this pain includes painkillers (including opioids and methadone), radiation and in rare incidents surgery. All of these options have significant limitations. Drugs eventually become less effective, especially for breakout [...]
Having your advanced prostate cancer progress to becoming castrate resistant is a major moment in our life. For many of us becoming castrate resistant signals a major change, a foreshadowing of what the future holds. Becoming castrate resistant heralds our eventual decline which can only lead us to one destination, our demise. How long it [...]